Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Now Viewing

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Comparison of PSA Thresholds

Key Themes:

• Comparison between ultra-low threshold (<0.02 ng/mL) and traditional thresholds (<0.1 or <0.2 ng/mL)
• Sensitivity and specificity considerations
• Prognostic value of different PSA cutoff points

Expert Insights:

• Dr Shore discussed the differences between the ultra-low PSA threshold and more conventional thresholds commonly used in clinical practice.

The conversation addressed the sensitivity, specificity, and potential prognostic significance of various PSA cutoff points.